. home.aspx



€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

January 06, 2020 / Labiotech.eu

Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The drug is designed to act like a common class of antibiotics called beta-lactams. Unlike beta-lactams, however, Mutabilis’ drug is designed to be impervious to being broken down by bacterial enzymes, a tactic used by bacteria to resist beta-lactams. Mutabilis’ drug could help to tackle the growing threat of antibiotic resistance in gram-negative bacteria, a group that contains some of the most drug-resistant pathogens.